Search clinical trials for: Placebo for ABT-267

Total 3532 results

AbbVie (prior sponsor, Abbott)

Completed

A Study to Evaluate Chronic Hepatitis C Infection in Treatment Experienced Adults

Chronic Hepatitis C Infection
AbbVie (prior sponsor, Abbott)

Completed

A Study to Evaluate Chronic Hepatitis C Infection

Chronic Hepatitis C Infection
AbbVie (prior sponsor, Abbott)

Completed

Study of ABT-267 in Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Infected Subjects

Chronic Hepatitis C | Hepatitis C Virus (HCV) Infection

United States, Puerto Rico
AbbVie

Completed

A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a Infection (PEARL-IV)

Chronic Hepatitis C Infection
AbbVie (prior sponsor, Abbott)

Completed

A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection (PEARL-III)

Chronic Hepatitis C Infection
AbbVie

Active, not recruiting

Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis (TRANSFORM-1)

Myelofibrosis (MF)

United States, Australia, Austria, Belgium, Bulgaria, Canada, Croatia, France, Germany, Greece, Israel, Italy, Japan, Korea, Republic of, Netherlands, New Zealand, Russian Federation, Serbia, South Africa, Spain, Sweden, Taiwan, Turkey and more
Research Foundation for Mental Hygiene, Inc.

Completed

Attention-Bias Modification Treatment for PTSD

Posttraumatic Stress Disorder (PTSD)

United States
Abbott

Completed

Pharmacokinetic Study of ABT-126 in Stable Subjects With Schizophrenia

Schizophrenia

United States
AbbVie (prior sponsor, Abbott)

Completed

Study of ABT-767 in Subjects With Breast Cancer 1 and Breast Cancer 2 (BRCA 1 and BRCA 2) Mutations and Solid Tumors or High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Primary Peritoneal Cancer | Fallopian Tube | Solid Tumors (e.g. Breast, Ovarian, Prostate, or Pancreatic) and Ovarian

Netherlands
AbbVie

Completed

A Phase 2a Study Evaluating the Safety and Efficacy of ABT-981 in Patients With Erosive Hand Osteoarthritis

Erosive Hand Osteoarthritis
AbbVie

Completed

Bioavailability of ABT-450 and ABT-267 With Ritonavir

Absolute Bioavailability

United Kingdom
AbbVie

Completed

A Study to Evaluate the Safety and Antiviral Effect of Multiple Doses of ABT-493 and ABT-530 in Adults With Genotype 1 Hepatitis C Virus (HCV)

Chronic Hepatitis C | Hepatitis C Virus | Compensated Cirrhosis
AbbVie (prior sponsor, Abbott)

Completed

A Study to Evaluate the Safety and Effect of Co-administration of ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Adults With Chronic Hepatitis C Virus Infection (PEARL-I)

Hepatitis C, Chronic
AbbVie

Terminated

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABT-957 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

Alzheimer's Disease

United States
AbbVie

Recruiting

Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis (TRANSFORM-2)

Myelofibrosis (MF)

United States, Australia, Austria, Belgium, Bulgaria, Canada, Croatia, Denmark, France, Germany, Greece, Hungary, Israel, Italy, Japan, Korea, Republic of, Poland, Puerto Rico, Russian Federation, Serbia, Spain, Taiwan, Turkey, United... and more
AbbVie (prior sponsor, Abbott)

Completed

A Study to Evaluate ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Japanese Adults With Chronic Hepatitis C Virus Infection

Chronic Hepatitis C Infection
AbbVie

Completed

A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) for Treatment of Chronic Hepatitis C Infection in Treatment-experienced Adults (MALACHITE II)

Chronic Hepatitis C Infection
AbbVie (prior sponsor, Abbott)

Completed

A Study to Evaluate the Safety and Effect of the Experimental Drugs ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Subjects With Chronic Hepatitis C (PEARL-II)

Chronic Hepatitis C Infection
AbbVie (prior sponsor, Abbott)

Completed

A Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267; (ABT-267 Also Known as Ombitasvir) and ABT-333 (Also Known as Dasabuvir) Coadministered With Ribavirin (RBV) in Hepatitis C Virus (HCV) Genotype 1-infected Adults With Compensated Cirrhosis (TURQUOISE-II)

Compensated Cirrhosis | Chronic Hepatitis C Infection
AbbVie

Completed

A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus (HCV) Genotype 2 Infection (ENDURANCE-2)

Chronic Hepatitis C Virus (HCV) Infection
AbbVie

Completed

An Open-label, Single Arm, Phase 2 Study to Evaluate ABT-450/r/ABT-267 and ABT-333 With Ribavirin (RBV) in Adults With Genotype 1 HCV Infection Taking Methadone or Buprenorphine

Chronic Hepatitis C | Chronic Hepatitis C Infection
Kathleen Ludwig

Available

Expanded Access Program of Venetoclax and Navitoclax for Pediatric Patients With Relapsed or Refractory ALL or LL

Relapsed Childhood ALL | Relapsed Childhood Lymphoblastic Lymphoma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Navitoclax, Venetoclax, and Decitabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Previously Treated With Venetoclax

Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia

United States
AbbVie

Completed

A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) in People With Hepatitis C Virus Infection Who Have Not Had Treatment Before (MALACHITE 1)

Chronic Hepatitis C Infection
AbbVie

Completed

A Study to Evaluate Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Treatment-Naïve Hepatitis C Virus Genotype 1b-Infected Adults (GARNET)

Hepatitis C Virus | Hepatitis C Infection
Assembly Biosciences

Completed

A Study of ABI-H2158 in Healthy Volunteers and Patients With Chronic Hepatitis B

Chronic Hepatitis B

Korea, Republic of, Australia, United States, Hong Kong, United Kingdom, China, New Zealand
AbbVie

Completed

A Multipart, Open-label Study to Evaluate the Safety and Efficacy of ABT-450/r/ABT-267 With and Without ABT-333 Coadministered With and Without Ribavirin in Adult With Genotype 1 or 4 Hepatitis C Virus (HCV) Infection and Human Immunodeficiency Virus, Type 1 Coinfection (TURQUOISE-I)

Hepatitis C Virus Infection | Chronic Hepatitis C | Human Immunodeficiency Virus Infection | Compensated Cirrhosis and Non-cirrhotics
Bridge Biotherapeutics, Inc.

Recruiting

First-in-Human Study of BBT-207 in Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation After Treatment With EGFR TKI

EGFR Mutant Advanced Non-Small Cell Lung Cancer

Korea, Republic of, United States
AbbVie

Completed

Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease

Chronic Hepatitis C | Hepatitis C Virus | Severe Renal Impairment | Compensated Cirrhosis | End-stage Renal Disease
AbbVie

No longer available

Expanded Access to Navitoclax

Myelofibrosis | Lymphoblastic Lymphoma | Acute Lymphocytic Leukemia (ALL)

United States
Centre Francois Baclesse
ARCAGY/ GINECO GROUP; French Cancer Research Hospital Program

Completed

A Study of ABT-263 as Single Agent in Women With Platinum Resistant/Refractory Recurrent Ovarian Cancer (MONAVI-1)

Platinum-resistant or Refractory Ovarian Cancer

France
Kezar Life Sciences, Inc.

Recruiting

KZR-261 in Subjects With Advanced Solid Malignancies

Advanced/Metastatic Solid Tumor

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing Nivolumab in Combination With Decitabine and Venetoclax in Patients With Newly Diagnosed TP53 Gene Mutated Acute Myeloid Leukemia

Acute Myeloid Leukemia

United States
AbbVie (prior sponsor, Abbott)
Genentech, Inc.

Completed

A Phase 1/2a Study of ABT-263 in Subjects With Small Cell Lung Cancer (SCLC) or Other Non-Hematological Malignancies

Small Cell Lung Carcinoma | Small Cell Lung Cancer

United States, Canada, United Kingdom
AbbVie

Completed

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-493 and ABT-530 With and Without Ribavirin in Adults With HCV Who Failed a Prior DAA Containing Therapy

Chronic Hepatitis C | Hepatitis C Virus | HCV | Direct-Acting Antiviral Agent (DAA)-Experienced
University of Sao Paulo General Hospital
Fundação de Amparo à Pesquisa do Estado de São Paulo

Completed

Acceptance and Commitment Therapy for Insomnia (ACT-I)

Insomnia

Brazil
AbbVie (prior sponsor, Abbott)

Completed

Open-label Extension Study of Navitoclax in Subjects With Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia

United States, Australia, Israel, Poland, Ukraine
Abbott
Genentech, Inc.

Completed

Assess the Oral Bioavailability of a New ABT-263 Formulation in Healthy Female Subjects

Healthy Female Subjects

United States
Abbott

Completed

Bioavailability of ABT-333 Tablet Versus First in Human (FIH) Capsule Formulation and Safety, Tolerability and PK Study of Single Doses of ABT-333 in Healthy Volunteers

HCV Infection

United States
Kamada, Ltd.

Completed

Phase II, Safety and Efficacy Study of Kamada-alpha-1-antitrypsin (AAT) for Inhalation"

Alpha-1 Antitrypsin Deficiency

United States
uniQure France SAS

Recruiting

AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy

Mesial Temporal Lobe Epilepsy

United States
AbbVie

Completed

Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) in Japanese Adults With Subgenotype 1b Chronic Hepatitis C Virus (HCV) Infection (GIFT I)

Chronic Hepatitis C Infection
AbbVie

Completed

ABT-450/Ritonavir/ ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co-Administered With Ribavirin (RBV) in Treatment Naïve and Treatment Experienced Asian Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Compensated Cirrhosis

Chronic Hepatitis C Virus (HCV)
National Cancer Institute (NCI)

Terminated

Navitoclax and Vistusertib in Treating Patients With Relapsed Small Cell Lung Cancer and Other Solid Tumors

Refractory Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Unresectable Solid Neoplasm | Recurrent Lung Small Cell Carcinoma | Stage IIIA Lung Small Cell Carcinoma AJCC v7 | Stage IIIB Lung Small Cell Carcinoma AJCC v7 | Stage IV Lung Small Cell... and other conditions

United States
AbbVie

Terminated

Safety and Tolerability Study of Mivebresib Tablet Alone or in Combination With Ruxolitinib Tablet or Navitoclax Tablet in Adult Participants With Myelofibrosis

Myelofibrosis (MF)

United States, Korea, Republic of, South Africa
Seres Therapeutics, Inc.

Terminated

A Study to Assess Efficacy and Safety of SER-287 in Adults With Active Mild-to-Moderate Ulcerative Colitis (ECO-RESET)

Ulcerative Colitis

United States, Canada
Karolinska Institutet
Region Stockholm

Completed

New Clinical Applications for Internet-based Cognitive Behavior Therapy for Insomnia and Depression

Insomnia | Major Depression | Minor Depression

Sweden
AbbVie

Completed

A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ-I)

Chronic Hepatitis C Virus (HCV) Infection Genotype 1

Algeria, Australia, Belgium, Bulgaria, Canada, Denmark, Finland, France, Germany, Greece, Israel, Italy, Mexico, Netherlands, Norway, Poland, Portugal, Romania, Russian Federation, Saudi Arabia, Spain, Switzerland, Turkey, Austria, Ireland and more
AbbVie

Completed

A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ-II)

Chronic Hepatitis C Virus (HCV) Infection Genotype 1

United States
AbbVie

Completed

Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT- 267 (ABT-450/r/ABT-267) in Japanese Adults With Genotype 2 Chronic Hepatitis C Virus (HCV) Infection (GIFT-II)

Hepatitis C Virus

3

Subscribe